TABLE 2.
Seroprevalence of hepatitis B virus, hepatitis C virus (HCV) and HIV infection for all patients tested as a part of the endoscopy epidemiological investigation
| Infection | Patients tested, n | Expected prevalence*, % (n expected) | Observed prevalence, n (%) | Interpretation (Pearson’s χ2 P) | Comparison population |
|---|---|---|---|---|---|
| HBsAg positive | 4703 | 2 (94) | 26 (0.55) | Lower (P<0.001) | Canada |
| Anti-HBc positive (past infection) | 4703 | 5–10 (235–470) | 366 (7.8) | Within range (NA) | Canada |
| Anti-HBc positive; HBsAg negative; HBcAg negative (immune) | 4703 | – | 1 (0.02) | – | – |
| HCV antibody positive | 4730 | 0.94 (44) | 62 (1.3) | Not different (P=0.08) | Ontario |
| HIV antibody positive | 5042 | 0.37 (19) | 0 (0) | Lower (P<0.001) | Ottawa |